IGF-1 LR3
Men's HealthMale-physiology practitioners evaluate IGF-1 LR3 against the HPG axis, androgenic markers, and downstream effects on body composition, libido, and recovery. Binds the IGF-1 receptor with full agonist activity The N-terminal extension (LR3 — Long arginine-3) prevents binding to IGF-binding proteins, so circulating LR3 remains 'free' and bioactive. Drives anabolic signalling, muscle satellite cell activation, and hyperplasia of muscle fibers in animal models.. For men running IGF-1 LR3 alongside TRT, post-cycle restarts, or fertility-aware protocols, baseline labs (total/free testosterone, LH, FSH, estradiol, prolactin, SHBG) and a 6-8 week follow-up panel are the standard monitoring framework at the 20-50 mcg 1-2x daily subq dose.
Key Takeaways
Male-physiology lens: IGF-1 LR3 is evaluated against HPG-axis interaction, TRT compatibility, and prostate / cardiovascular considerations. Mechanism: Binds the IGF-1 receptor with full agonist activity. Male monitoring: baseline testosterone (total/free), LH, FSH, estradiol, prolactin, SHBG; 6-8 week follow-up panel. Male dose: 20-50 mcg 1-2x daily subq via subq; cycle 8-12 weeks. Male-physiology stack partners: Kisspeptin, Gonadorelin (GnRH), PT-141.
Male users' practical questions about IGF-1 LR3 reduce to: hormonal coherence, TRT integration, and prostate / cardiovascular safety. Binds the IGF-1 receptor with full agonist activity. The N-terminal extension (LR3 — Long arginine-3) prevents binding to IGF-binding proteins, so circulating LR3 remains 'free' and bioactive. Drives anabolic signalling, muscle satellite cell activation, and hyperplasia of muscle fibers in animal models. The mechanism shapes the answer to each. The subsections below work through HPG-axis impact and TRT compatibility before examining the body composition and male-physiology response.
Compatibility with TRT and post-cycle protocols
For men currently on TRT or planning a post-cycle restart, IGF-1 LR3 is typically compatible because it does not directly engage the HPG axis. The dominant interaction to watch for is on the metabolic and recovery layers rather than the hormonal layer. Where the molecule's pharmacology overlaps with HCG, gonadorelin, or kisspeptin, dose layering is the standard approach.
Interaction with the HPG axis
IGF-1 LR3's relationship to the male HPG axis is one of the central practical questions. Direct receptor-level engagement of the HPG axis is not the principal mechanism, but downstream effects on testosterone, LH/FSH, and prolactin can still occur and warrant baseline and follow-up labs in male users. The practical takeaway is that any male user beginning a course of IGF-1 LR3 should have a baseline hormone panel and a follow-up at 6–8 weeks to detect drift.
Sexual function and prostate considerations
Where IGF-1 LR3 alters circulating LH, testosterone, or local androgen signalling, prostate considerations become relevant for men over 40. Baseline PSA, periodic re-check, and avoidance of stacking that compounds androgenic load are all reasonable precautions. For molecules whose effects are predominantly outside the HPG axis, the prostate consideration is largely background.
For hpg axis support in male users, IGF-1 LR3 is most-effective when paired with comprehensive labs (testosterone total/free, LH, FSH, estradiol sensitive, prolactin, SHBG) at baseline and follow-up. Cycle length 8–12 weeks with re-evaluation.
Cardiovascular Health (Male) in men responds to IGF-1 LR3 with effect sizes that vary substantially by baseline status — men with documented suboptimal status respond more strongly than those at the upper end of normal. The protocol pattern in clinical use reflects this.
Where male users target erectile function, IGF-1 LR3 is typically integrated with the broader hormonal protocol — TRT, kisspeptin, gonadorelin, or HCG — rather than used in isolation. The integration approach varies by clinic.
For strength & power in male users, IGF-1 LR3 is most-effective when paired with comprehensive labs (testosterone total/free, LH, FSH, estradiol sensitive, prolactin, SHBG) at baseline and follow-up. Cycle length 8–12 weeks with re-evaluation.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 20-50 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 12-50 mcg | 4–6 weeks initial cycle |
| Men's Health focus | SubQ | 20-50 mcg | 1-2x daily SubQ |
| Maintenance phase | SubQ | 14-50 mcg | Ongoing with periodic pauses |
Dose timing for IGF-1 LR3 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
IGF-1 LR3 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from men's-health clinicians.
- IGF-1 LR3 + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with IGF-1 LR3's mechanism in male physiology protocols.
- IGF-1 LR3 + Gonadorelin (GnRH): Binds the GnRH receptor on anterior pituitary gonadotrophs in a pulsatile fashion to stimulate LH (and to a lesser extent FSH) release. Pairs naturally with IGF-1 LR3's mechanism in male physiology protocols.
- IGF-1 LR3 + PT-141: Activates MC4R in the hypothalamus and other CNS regions involved in sexual response. Pairs naturally with IGF-1 LR3's mechanism in male physiology protocols.
- IGF-1 LR3 + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with IGF-1 LR3's mechanism in male physiology protocols.
Hypoglycaemia risk (engages insulin receptor weakly). Site-specific muscle growth observed. Long-term human safety not established. Concerns regarding tumour growth in pre-existing malignancy.
Lens-specific safety considerations for male physiology use of IGF-1 LR3: Hypoglycaemia risk (engages insulin receptor weakly). Site-specific muscle growth observed. Long-term human safety not established. Concerns regarding tumour growth in pre-existing malignancy. Additional male physiology monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| IGF-1 LR3 | Modified insulin-like growth factor 1 | ~20-30 hr (vs ~10 min for native IGF-1) | Men's Health |
| Kisspeptin | Hypothalamic upstream regulator of GnRH | ~28 min IV | The upstream master regulator of GnRH neurons — driving the entire HPG axis from above |
| Gonadorelin (GnRH) | Hypothalamic decapeptide | ~2-4 min | The natural decapeptide that drives pituitary release of LH and FSH — used clinically and increasingly as an HCG alternative during testosterone therapy |
| PT-141 | Melanocortin receptor agonist | ~2-3 hr | An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women |
How does IGF-1 LR3 affect the HPG axis?
Is IGF-1 LR3 compatible with TRT?
Will IGF-1 LR3 affect fertility or sperm quality?
Can I use IGF-1 LR3 during a cut?
How does IGF-1 LR3's half-life affect dosing?
What is the standard dosing protocol for IGF-1 LR3?
Start a IGF-1 LR3 Protocol
Alukard provides physician-supervised men's health protocols with GMP-certified IGF-1 LR3 and GMP-certified compounds with comprehensive hormone panels.
Get ProtocolQuick Facts
- Molecular weight
- 9111 Da
- Sequence length
- 83 aa
- Half-life
- ~20-30 hr (vs ~10 min for native IGF-1)
- WADA
- Banned (S2)
- FDA
- Unapproved (research reagent)
- Research
- Animal models; off-label use widespread
All male physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for IGF-1 LR3 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Male Physiology Protocol for IGF-1 LR3
Alukard provides physician-supervised men's health protocols with GMP-certified compounds with comprehensive hormone panels.
HIPAA Compliant · GMP Certified · Physician Supervised